{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:42:48Z","timestamp":1789522968455,"version":"build-2803163510"},"reference-count":38,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009160","name":"Universit\u00e9 Toulouse III - Paul Sabatier","doi-asserted-by":"publisher","award":["French government (IDEX 2012)"],"award-info":[{"award-number":["French government (IDEX 2012)"]}],"id":[{"id":"10.13039\/501100009160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,5,2]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Besides the interest of an early detection of ovarian cancer, there is an urgent need for new predictive and prognostic biomarkers of tumor development and cancer treatment. In healthy patients, circulating blood monocytes are typically subdivided into classical (85%), intermediate (5%) and non-classical (10%) populations. Although these circulating monocyte subsets have been suggested as biomarkers in several diseases, few studies have investigate their potential as a predictive signature for tumor immune status,tumor growth and treatment adaptation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, we used a homogeneous cohort of 28 chemotherapy-na\u00efve patients with ovarian cancer to evaluate monocyte subsets as biomarkers of the ascites immunological status. We evaluated the correlations between circulating monocyte subsets and immune cells and tumor burden in peritoneal ascites. Moreover, to validate the use of circulating monocyte subsets tofollow tumor progression and treatment response, we characterized blood monocytes from ovarian cancer patients included in a phase 1 clinical trial at baseline and following murlentamab treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrate here a robust expansion of the intermediate blood monocytes (IBMs) in ovarian cancer patients. We establish a significant positive correlation between IBM percentage and tumor\u2013associate macrophages with a CCR2<jats:sup>high<\/jats:sup>\/CD163<jats:sup>high<\/jats:sup>\/CD206<jats:sup>high<\/jats:sup>\/CD86<jats:sup>low<\/jats:sup>profile. Moreover, IBM expansion is associated with a decreased effector\/regulatory T-cell ratio in ascites and with the presence of soluble immunosuppressive mediators. We also establish that IBM proportion positively correlates with the peritoneum tumor burden. Finally, the study of IBMs in patients with ovarian cancer under immunotherapy during the phase clinical trial supports IBMs to follow the evolution of tumor development and the treatment adaptation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study, which links IBM level with immunosuppression and tumor burden in peritoneum, identifies IBMs as apotential predictive signature of ascites immune status and as a biomarker ofovarian cancer development and treatment response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>EudraCT: 2015-004252-22 <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02978755\">NCT02978755<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000472","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T05:46:50Z","timestamp":1591336010000},"page":"e000472","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":45,"title":["Circulating CD14<sup>high<\/sup> CD16<sup>low<\/sup> intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02978755","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"M\u00e9lissa","family":"Prat","sequence":"first","affiliation":[{"name":"UMR152 Pharmadev, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, Occitanie, France"},{"name":"UMR152 Pharmadev, IRD, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Le Naour","sequence":"additional","affiliation":[{"name":"UMR152 Pharmadev, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, Occitanie, France"},{"name":"UMR152 Pharmadev, IRD, Toulouse, France"},{"name":"UMR1037, CRCT, Toulouse, Midi-Pyr\u00e9n\u00e9es, France"},{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Coulson","sequence":"additional","affiliation":[{"name":"UMR152 Pharmadev, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, Occitanie, France"},{"name":"UMR152 Pharmadev, IRD, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Lem\u00e9e","sequence":"additional","affiliation":[{"name":"Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Leray","sequence":"additional","affiliation":[{"name":"UMR1037, CRCT, Toulouse, Midi-Pyr\u00e9n\u00e9es, France"},{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godefroy","family":"Jacquemin","sequence":"additional","affiliation":[{"name":"UMR152 Pharmadev, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, Occitanie, France"},{"name":"UMR152 Pharmadev, IRD, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna Chirine","family":"Rahabi","sequence":"additional","affiliation":[{"name":"UMR152 Pharmadev, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, Occitanie, France"},{"name":"UMR152 Pharmadev, IRD, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"UMR1037, CRCT, Toulouse, Midi-Pyr\u00e9n\u00e9es, France"},{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Authier","sequence":"additional","affiliation":[{"name":"UMR152 Pharmadev, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, Occitanie, France"},{"name":"UMR152 Pharmadev, IRD, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Ferron","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Barret","sequence":"additional","affiliation":[{"name":"Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Martinez","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Ayyoub","sequence":"additional","affiliation":[{"name":"UMR1037, CRCT, Toulouse, Midi-Pyr\u00e9n\u00e9es, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Tabah-Fisch","sequence":"additional","affiliation":[{"name":"Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Prost","sequence":"additional","affiliation":[{"name":"Gamamabs Pharma, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Couderc","sequence":"additional","affiliation":[{"name":"UMR1037, CRCT, Toulouse, Midi-Pyr\u00e9n\u00e9es, France"},{"name":"Institut Claudius Regaud, IUCT Oncopole, Toulouse, Languedoc-Roussillon-Midi, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7781-3323","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Coste","sequence":"additional","affiliation":[{"name":"UMR152 Pharmadev, Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, Occitanie, France"},{"name":"UMR152 Pharmadev, IRD, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"2025100311415724000_8.1.e000472.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"2025100311415724000_8.1.e000472.2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"The Lancet"},{"key":"2025100311415724000_8.1.e000472.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"2025100311415724000_8.1.e000472.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35860-z","article-title":"Debio 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death","volume":"8","author":"Thibault","year":"2018","journal-title":"Sci Rep"},{"key":"2025100311415724000_8.1.e000472.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.11.030"},{"key":"2025100311415724000_8.1.e000472.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.031"},{"key":"2025100311415724000_8.1.e000472.7","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8297-3"},{"key":"2025100311415724000_8.1.e000472.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04321.x"},{"key":"2025100311415724000_8.1.e000472.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04200.x"},{"key":"2025100311415724000_8.1.e000472.10","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4466"},{"key":"2025100311415724000_8.1.e000472.11","first-page":"2875","article-title":"Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity","volume":"29","author":"Giuntoli","year":"2009","journal-title":"Anticancer Res"},{"key":"2025100311415724000_8.1.e000472.12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00256"},{"key":"2025100311415724000_8.1.e000472.13","doi-asserted-by":"crossref","first-page":"e1424672","DOI":"10.1080\/2162402X.2018.1424672","article-title":"Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells","volume":"7","author":"Lieber","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100311415724000_8.1.e000472.14","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/labinvest.2011.116","article-title":"Anti-M\u00fcllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis","volume":"91","author":"Anttonen","year":"2011","journal-title":"Lab Invest"},{"key":"2025100311415724000_8.1.e000472.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.09.010"},{"key":"2025100311415724000_8.1.e000472.16","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2002.1380"},{"key":"2025100311415724000_8.1.e000472.17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/13697137.2017.1406911","article-title":"Clinicopathological and prognostic significance of platelet count in patients with ovarian cancer","volume":"21","author":"Zhou","year":"2018","journal-title":"Climacteric"},{"key":"2025100311415724000_8.1.e000472.18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5542","article-title":"A first-in-human study of monoclonal antibody GM102 in patients with anti-Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers","volume":"36","author":"Leary","year":"2018","journal-title":"JCO"},{"key":"2025100311415724000_8.1.e000472.19","doi-asserted-by":"crossref","first-page":"99950","DOI":"10.18632\/oncotarget.21556","article-title":"The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages","volume":"8","author":"Bougherara","year":"2017","journal-title":"Oncotarget"},{"key":"2025100311415724000_8.1.e000472.20","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1172\/JCI93182","article-title":"Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy","volume":"127","author":"Jung","year":"2017","journal-title":"J Clin Invest"},{"key":"2025100311415724000_8.1.e000472.21","doi-asserted-by":"publisher","DOI":"10.1038\/srep13886"},{"key":"2025100311415724000_8.1.e000472.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.08.011"},{"key":"2025100311415724000_8.1.e000472.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-326827"},{"key":"2025100311415724000_8.1.e000472.24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5114\/ceji.2012.32725","article-title":"Clinical immunology gastric cancer increase the percentage of intermediate (CD14++CD16+) and nonclassical (CD14+CD16+) monocytes","volume":"4","author":"Eljaszewicz","year":"2012","journal-title":"Central European Journal of Immunology"},{"key":"2025100311415724000_8.1.e000472.25","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.53"},{"key":"2025100311415724000_8.1.e000472.26","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3892\/or.2015.4088","article-title":"Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia\u00a0patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163","volume":"34","author":"Lapuc","year":"2015","journal-title":"Oncol Rep"},{"key":"2025100311415724000_8.1.e000472.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.2.669"},{"key":"2025100311415724000_8.1.e000472.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.07.172"},{"key":"2025100311415724000_8.1.e000472.29","first-page":"999","article-title":"Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1","volume":"3","author":"Chambers","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2025100311415724000_8.1.e000472.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0525"},{"key":"2025100311415724000_8.1.e000472.31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0124"},{"key":"2025100311415724000_8.1.e000472.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038541"},{"key":"2025100311415724000_8.1.e000472.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2009.02369.x"},{"key":"2025100311415724000_8.1.e000472.34","doi-asserted-by":"publisher","DOI":"10.7785\/tcrt.2012.500312"},{"key":"2025100311415724000_8.1.e000472.35","first-page":"57","article-title":"Scavenger receptor CD163 and its biological functions","volume":"52","author":"Onofre","year":"2009","journal-title":"Acta Medica"},{"key":"2025100311415724000_8.1.e000472.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-072587"},{"key":"2025100311415724000_8.1.e000472.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4005"},{"key":"2025100311415724000_8.1.e000472.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:42:05Z","timestamp":1759516925000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,4]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jitc-2019-000472"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000472","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}